<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mrj</journal-id><journal-title-group><journal-title xml:lang="ru">Современная ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Modern Rheumatology Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1996-7012</issn><issn pub-type="epub">2310-158X</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1996-7012-2019-1-64-70</article-id><article-id custom-type="elpub" pub-id-type="custom">mrj-888</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL INVESTIGATIONS</subject></subj-group></article-categories><title-group><article-title>Экспрессия генов метаболизма глюкозы и деструкции суставов при развитии сахарного диабета у больных остеоартритом</article-title><trans-title-group xml:lang="en"><trans-title>Expression of genes related to glucose metabolism and joint destruction in the development of diabetes mellitus in patients with osteoarthritis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Четина</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Chetina</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Елена Васильевна Четина</p><p>115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>Elena Vasilyevna Chetina</p><p>34A, Kashirskoye Shosse, Moscow 115522</p></bio><email xlink:type="simple">etchetina@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шарапова</surname><given-names>Е. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Sharapova</surname><given-names>E. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoye Shosse, Moscow 115522</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кашеварова</surname><given-names>Н. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Kashevarova</surname><given-names>N. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoye Shosse, Moscow 115522</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Таскина</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Taskina</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoye Shosse, Moscow 115522</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Маркова</surname><given-names>Г. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Markova</surname><given-names>G. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoye Shosse, Moscow 115522</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Алексеева</surname><given-names>Л. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Alekseeva</surname><given-names>L. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoye Shosse, Moscow 115522</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лила</surname><given-names>А. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Lila</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoye Shosse, Moscow 115522</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>26</day><month>03</month><year>2019</year></pub-date><volume>13</volume><issue>1</issue><fpage>64</fpage><lpage>70</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Четина Е.В., Шарапова Е.П., Кашеварова Н.Г., Таскина Е.А., Маркова Г.А., Алексеева Л.И., Лила А.М., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Четина Е.В., Шарапова Е.П., Кашеварова Н.Г., Таскина Е.А., Маркова Г.А., Алексеева Л.И., Лила А.М.</copyright-holder><copyright-holder xml:lang="en">Chetina E.V., Sharapova E.P., Kashevarova N.G., Taskina E.A., Markova G.A., Alekseeva L.I., Lila A.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://mrj.ima-press.net/mrj/article/view/888">https://mrj.ima-press.net/mrj/article/view/888</self-uri><abstract><p>У многих пациентов с остеоартритом (ОА) имеются коморбидные заболевания. Причем эта ассоциация чаще наблюдается по мере старения. Одной из коморбидных патологий ОА является сахарный диабет 2-го типа (СД2). В связи с увеличением распространенности и случаев сосуществования этих двух заболеваний предполагается, что гипергликемия, свойственная СД2, может неблагоприятно влиять на ткани сустава и увеличивать тяжесть ОА. Однако молекулярные механизмы возникновения СД у больных ОА неясны.</p><p>Цель работы — проследить динамику развития СД2 у больных ОА на уровне экспрессии генов, ассоциированных с метаболизмом глюкозы, деструкцией суставов и общей регуляцией метаболических процессов.</p><sec><title>Пациенты и методы</title><p>Пациенты и методы. Наблюдение 3 больных ОА проводили в течение 4—6 лет, включая год начала СД2. Клиническое состояние больных анализировали раз в год. Общую РНК ежегодно выделяли из крови и использовали для определения уровня экспрессии генов в полимеразной цепной реакции в режиме реального времени.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. Показано, что развитие СД2 у больных ОА сопровождалось увеличением экспрессии генов гликолиза, цикла Кребса, пентозофосфатного пути, матриксных металлопротеиназ и регуляторов метаболизма АМРК и mTOR. Напротив, уровень регулятора гипоксии HIFla и генов гексозаминового пути снижался.</p></sec><sec><title>Выводы</title><p>Выводы. Возникновение СД2 на фоне ОА, вероятно, связано с увеличением потребности клеток в энергии АТФ и сопровождается активацией путей ассимиляции глюкозы, а также увеличением экспрессии генов, ответственных за разрушение внеклеточного матрикса. Это может быть вызвано нарушением гликозилирования белков вследствие ингибирования гексозаминового пути.</p></sec></abstract><trans-abstract xml:lang="en"><p>Many patients with osteoarthritis (OA) tend to have comorbidities. This tendency is more frequently observed to increase with age. One of the comorbidities is type 2 diabetes mellitus (T2DM). Due to the higher prevalence of coexistence of these two conditions, it has been suggested that T2DM-associated hyperglycemia may adversely affect joint tissues and increase OA severity. However, the molecular mechanisms in the development of DM in patients with OA remain unclear.</p><sec><title>Objective</title><p>Objective: to trace the dynamics of T2DM development in patients with OA at the level of the expression of genes associated with glucose metabolism, joint destruction, and general regulation of metabolic processes.</p></sec><sec><title>Patients and methods</title><p>Patients and methods. Three patients with OA were followed up for 4—6 years, including the year of onset of T2DM. The clinical condition of the patients was analyzed once a year. Total RNA was annually isolated from their blood and used to determine the level of gene expression by real-time polymerase chain reaction.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. The development of T2DM was shown to be accompanied by the increased expression of genes related to glycolysis, Krebs cycle, pentose phosphate pathway, matrix metalloproteinases and regulators of AMPKand mTOR metabolism. By contrast, the level of the hypoxia regulator HIF1a and hexosamine pathway genes was decreased.</p></sec><sec><title>Conclusion</title><p>Conclusion. The occurrence of T2DM in the presence of OA is likely to be associated with the higher needs for cells for ATP energy and is accompanied by activation of the glucose assimilation pathways, as well as by the increased expression of the genes responsible for extracellular matrix destruction. This may be caused by impaired protein glycosylation due to inhibition of the hexosamine pathway.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>остеоартрит</kwd><kwd>сахарный диабет</kwd><kwd>экспрессия генов</kwd><kwd>энергетический метаболизм</kwd><kwd>кровь</kwd></kwd-group><kwd-group xml:lang="en"><kwd>osteoarthritis</kwd><kwd>diabetes mellitus</kwd><kwd>gene expression</kwd><kwd>energy metabolism</kwd><kwd>blood</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Courties A, Sellam J. Osteoarthritis and type 2 diabetes mellitus: What are the links? Diabetes Res Clin Pract. 2016 Dec;122: 198-206. doi: 10.1016/j.diabres.2016.10.021. Epub 2016 Nov 5.</mixed-citation><mixed-citation xml:lang="en">Courties A, Sellam J. Osteoarthritis and type 2 diabetes mellitus: What are the links? Diabetes Res Clin Pract. 2016 Dec;122: 198-206. doi: 10.1016/j.diabres.2016.10.021. Epub 2016 Nov 5.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Bijlsma JW, Berenbaum F, Lafeber FP. Osteoarthritis: an update with relevance for clinical practice. Lancet. 2011 Jun 18;377(9783):2115-26. doi: 10.1016/S0140-6736(11)60243-2.</mixed-citation><mixed-citation xml:lang="en">Bijlsma JW, Berenbaum F, Lafeber FP. Osteoarthritis: an update with relevance for clinical practice. Lancet. 2011 Jun 18;377(9783):2115-26. doi: 10.1016/S0140-6736(11)60243-2.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Felson DT. Clinical practice. Osteoarthritis of the knee. N Engl J Med. 2006 Feb 23; 354(8):841-8.</mixed-citation><mixed-citation xml:lang="en">Felson DT. Clinical practice. Osteoarthritis of the knee. N Engl J Med. 2006 Feb 23; 354(8):841-8.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Zullig LL, Bosworth HB, Jeffreys AS, et al. The association of comorbid conditions with patient-reported outcomes in Veterans with hip and knee osteoarthritis. Clin Rheumatol. 2015 Aug;34(8):1435-41. doi: 10.1007/s10067-014-2707-y. Epub 2014 Jun 12.</mixed-citation><mixed-citation xml:lang="en">Zullig LL, Bosworth HB, Jeffreys AS, et al. The association of comorbid conditions with patient-reported outcomes in Veterans with hip and knee osteoarthritis. Clin Rheumatol. 2015 Aug;34(8):1435-41. doi: 10.1007/s10067-014-2707-y. Epub 2014 Jun 12.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Parkinson L, Waters DL, Franck L. Systematic review of the impact of osteoarthritis on health outcomes for comorbid disease in older people. Osteoarthritis Cartilage. 2017 Nov;25(11):1751-1770. doi: 10.1016/jjoca.2017.07.008. Epub 2017 Jul 11.</mixed-citation><mixed-citation xml:lang="en">Parkinson L, Waters DL, Franck L. Systematic review of the impact of osteoarthritis on health outcomes for comorbid disease in older people. Osteoarthritis Cartilage. 2017 Nov;25(11):1751-1770. doi: 10.1016/jjoca.2017.07.008. Epub 2017 Jul 11.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Singh JA, Lewallen DG. Time trends in the characteristics of patients undergoing primary total knee arthroplasty. Arthritis Care Res (Hoboken). 2014 Jun;66(6):897-906. doi: 10.1002/acr.22233.</mixed-citation><mixed-citation xml:lang="en">Singh JA, Lewallen DG. Time trends in the characteristics of patients undergoing primary total knee arthroplasty. Arthritis Care Res (Hoboken). 2014 Jun;66(6):897-906. doi: 10.1002/acr.22233.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Berenbaum F, Griffin TM, Liu-Bryan R. Metabolic Regulation of Inflammation in Osteoarthritis. Arthritis Rheumatol. 2017 Jan; 69(1):9-21. doi: 10.1002/art.39842.</mixed-citation><mixed-citation xml:lang="en">Berenbaum F, Griffin TM, Liu-Bryan R. Metabolic Regulation of Inflammation in Osteoarthritis. Arthritis Rheumatol. 2017 Jan; 69(1):9-21. doi: 10.1002/art.39842.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Tchetina EV, Markova GA, Poole AR, et al. Deferoxamine suppresses collagen cleavage, protease, cytokine, COL10A1 expression and upregulates AMPK and Krebs cycle genes in human osteoarthritic cartilage. Int J Rheumatol. 2016;2016:6432867. doi: 10.1155/2016/6432867. Epub 2016 Nov 30.</mixed-citation><mixed-citation xml:lang="en">Tchetina EV, Markova GA, Poole AR, et al. Deferoxamine suppresses collagen cleavage, protease, cytokine, COL10A1 expression and upregulates AMPK and Krebs cycle genes in human osteoarthritic cartilage. Int J Rheumatol. 2016;2016:6432867. doi: 10.1155/2016/6432867. Epub 2016 Nov 30.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Tchetina EV, Poole AR, Zaitseva EM, et al. Differences in mTOR (mammalian target of rapamycin) gene expression in the peripheral blood and articular cartilages of osteoarthritic patients and disease activity. Arthritis. 2013; 2013:461486. doi: 10.1155/2013/461486. Epub 2013 Jun 25.</mixed-citation><mixed-citation xml:lang="en">Tchetina EV, Poole AR, Zaitseva EM, et al. Differences in mTOR (mammalian target of rapamycin) gene expression in the peripheral blood and articular cartilages of osteoarthritic patients and disease activity. Arthritis. 2013; 2013:461486. doi: 10.1155/2013/461486. Epub 2013 Jun 25.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. (2011) Nat. Rev. Mol. Cell. Biol. 2011; 12(1):21-35. doi: 10.1038/nrm3025.</mixed-citation><mixed-citation xml:lang="en">Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. (2011) Nat. Rev. Mol. Cell. Biol. 2011; 12(1):21-35. doi: 10.1038/nrm3025.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Jeon SM. Regulation and function of AMPK in physiology and diseases. Exp Mol Med. 2016 Jul 15;48(7):e245. doi: 10.1038/emm.2016.81.</mixed-citation><mixed-citation xml:lang="en">Jeon SM. Regulation and function of AMPK in physiology and diseases. Exp Mol Med. 2016 Jul 15;48(7):e245. doi: 10.1038/emm.2016.81.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Xiao H, Gu Z, Wang G, et al. The possible mechanisms underlying the impairment of HIF-1a pathway signaling in hyperglycemia and the beneficial effects of certain therapies. Int JMed Sci. 2013 Aug 22;10(10):1412-21. doi: 10.7150/ijms.5630.eCollection 2013.</mixed-citation><mixed-citation xml:lang="en">Xiao H, Gu Z, Wang G, et al. The possible mechanisms underlying the impairment of HIF-1a pathway signaling in hyperglycemia and the beneficial effects of certain therapies. Int JMed Sci. 2013 Aug 22;10(10):1412-21. doi: 10.7150/ijms.5630.eCollection 2013.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Kim J. Regulation of Immune Cell Functions by Metabolic Reprogramming. J Immunol Res. 2018 Feb 13;2018: 8605471. doi: 10.1155/2018/8605471.eCollection 2018.</mixed-citation><mixed-citation xml:lang="en">Kim J. Regulation of Immune Cell Functions by Metabolic Reprogramming. J Immunol Res. 2018 Feb 13;2018: 8605471. doi: 10.1155/2018/8605471.eCollection 2018.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Yang Z, Matteson EL, Goronzy JJ, et al. T-cell metabolism in autoimmune disease. Arthritis Res Ther. 2015 Feb 11;17:29. doi: 10.1186/s13075-015-0542-4.</mixed-citation><mixed-citation xml:lang="en">Yang Z, Matteson EL, Goronzy JJ, et al. T-cell metabolism in autoimmune disease. Arthritis Res Ther. 2015 Feb 11;17:29. doi: 10.1186/s13075-015-0542-4.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Herbel C, Patsoukis N, Bardhan K, et al. Clinical significance of T cell metabolic reprogramming in cancer. Clin Transl Med. 2016 Dec;5(1):29. doi: 10.1186/s40169-016-0110-9. Epub 2016 Aug 10.</mixed-citation><mixed-citation xml:lang="en">Herbel C, Patsoukis N, Bardhan K, et al. Clinical significance of T cell metabolic reprogramming in cancer. Clin Transl Med. 2016 Dec;5(1):29. doi: 10.1186/s40169-016-0110-9. Epub 2016 Aug 10.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Marshall S. Role of insulin, adipocyte hormones, and nutrient-sensing pathways in regulating fuel metabolism and energy homeostasis: a nutritional perspective of diabetes, obesity, and cancer. Sci STKE. 2006 Aug 1; 2006(346):re7.</mixed-citation><mixed-citation xml:lang="en">Marshall S. Role of insulin, adipocyte hormones, and nutrient-sensing pathways in regulating fuel metabolism and energy homeostasis: a nutritional perspective of diabetes, obesity, and cancer. Sci STKE. 2006 Aug 1; 2006(346):re7.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Четина ЕВ, ДиБатиста Д, Пул АР. Роль простагландина E2 в ингибировании разрушения коллагена суставного хряща больных остеоартрозом. Научно-практическая pевматоло™я. 2009;47(3):18-24. doi: 10.14412/1995-4484-2009-1308</mixed-citation><mixed-citation xml:lang="en">Chetina EV, DiBatista D, Pul AR. Prostaglandin E2 role in inhibition of joint cartilage collagen destruction in patients with osteoarthritis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2009;47(3):18-24. (In Russ.). doi: 10.14412/1995-4484-2009-1308</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Straub RH, Cutolo M, Buttgereit F, et al. Energy regulation and neuroendocrine-immune control in chronic inflammatory diseases. J Intern Med. 2010 Jun;267(6):543-60. doi: 10.1111/j.1365-2796.2010.02218.x. Epub 2010 Jan 28.</mixed-citation><mixed-citation xml:lang="en">Straub RH, Cutolo M, Buttgereit F, et al. Energy regulation and neuroendocrine-immune control in chronic inflammatory diseases. J Intern Med. 2010 Jun;267(6):543-60. doi: 10.1111/j.1365-2796.2010.02218.x. Epub 2010 Jan 28.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Vallon V, Komers R. Pathophysiology of the diabetic kidney. Compr Physiol. 2011 Jul; 1(3):1175-232. doi: 10.1002/cphy.c100049.</mixed-citation><mixed-citation xml:lang="en">Vallon V, Komers R. Pathophysiology of the diabetic kidney. Compr Physiol. 2011 Jul; 1(3):1175-232. doi: 10.1002/cphy.c100049.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Ширинский ВС, Ширинский ИВ. Коморбидные заболевания — актуальная проблема клинической медицины. Сибирский медицинский журнал. 2014;29(1): 7-12.</mixed-citation><mixed-citation xml:lang="en">Shirinskii VS, Shirinskii IV. Comorbid diseases-the actual problem of clinical medicine. Sibirskii meditsinskii zhurnal. 2014; 29(1):7-12. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Ленинджер А. Основы биохимии. Москва: Мир; 1985. 367 c.</mixed-citation><mixed-citation xml:lang="en">Leninger A. Osnovy biokhimii [Basics of biochemistry]. Moscow: Mir; 1985. 367 p.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
